Xilio Therapeutics, Inc.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative, tumor-activated immunotherapy treatments for cancer. Their mission is to revolutionize cancer care by creating therapies that effectively target tumors while minimizing the severe systemic side effects common with current immuno-oncology treatments. Xilio leverages its proprietary GPS platform to engineer a range of immune-modulatory molecules, including antibodies, cytokines, and bispecific molecules, which are designed to be activated specifically within the tumor microenvironment.

The company has a robust pipeline of promising products in clinical and preclinical development, including XTX101, a tumor-activated anti-CTLA-4 antibody, and XTX301, a tumor-activated IL-12 cytokine. Their innovative approach has garnered attention from investors and analysts, as evidenced by their stock listing on the NASDAQ under the ticker symbol XLO. Xilio is committed to pushing the boundaries of cancer treatment, with the ultimate goal of improving patient outcomes and quality of life.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing tumor-activated immuno-oncology therapies. Their mission is to revolutionize cancer treatment by creating therapies that eliminate tumors at their source, providing effective and long-lasting cures without the harsh systemic side effects of current treatments. They leverage their proprietary platform technology to engineer molecules that target and activate within the tumor microenvironment, maximizing therapeutic benefits while minimizing side effects.

Xilio Therapeutics promotes a culture focused on innovation and collaboration, driven by a shared passion for developing groundbreaking cancer therapies. The company fosters a team-oriented environment where employees feel valued and empowered to contribute their unique expertise. They are committed to creating a diverse and inclusive workplace where everyone feels respected and supported, ultimately aiming to cultivate a culture that thrives on scientific excellence and a deep commitment to improving the lives of cancer patients.